Αποτελέσματα Αναζήτησης
10 Ιαν 2024 · The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings.
- ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Clinical practice guidelines serve as a guide for doctors...
- Management of Hereditary Breast Cancer: American Society of Clinical ...
Providers caring for patients with breast cancer with...
- ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical products, procedures, or tests (modality-oriented).
3 Απρ 2020 · Providers caring for patients with breast cancer with germline BRCA1/2 mutations should discuss treatment options related to the index cancer and the increased risk of contralateral breast cancer (CBC) and new ipsilateral breast cancer.
Systemic Treatment of Patients With Metastatic Breast Cancer Resource–Stratified Guideline January 10, 2024 Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
These adjuvant chemotherapy regimens can be used for patients with early breast cancer: Fluorouracil-epirubicin-cyclophosphamide X 3 → docetaxel X 3 (superior to fluorouracil-epirubicin-cyclophosphamide X 6) Doxorubicin-cyclophosphamide X 4 → docetaxel X 4 (superior to doxorubicin-cyclophosphamide X 4)
The ASCO Clinical Practice Guidelines Committee guideline process includes: a systematic literature review by ASCO guidelines staff. an expert panel provides critical review and evidence interpretation to inform guideline recommendations. final guideline approval by ASCO CPGC.
Results: Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement. Recommendations: Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available.
